Survodutide

Weekly dual agonist. Phase 2 obesity trial titrated from 0.6 mg up to 2.4–4.8 mg.

 

What it does / how it works

Same dual idea as other glucagon/GLP-1 agonists: eat less via GLP-1, burn more via glucagon. Titration exists because both receptors drive nausea.

Class Glucagon / GLP-1 dual agonist
Typical vial 10 mg
Reconstitution 1–2 mL BAC water
Storage after mix 2–8°C, use within 28 days

Protocol

Goal Dose How often How long Route
Weeks 1-4 0.6 mg Once weekly 4 weeks SubQ
Weeks 5-8 1.2 mg Once weekly 4 weeks SubQ
Weeks 9-12 1.8 mg Once weekly 4 weeks SubQ
Week 13 on 2.4-4.8 mg Once weekly Up to 46 weeks SubQ

Watch: GI-limited. Hold a step if nausea persists.

Survodutide FAQ — Australia

Survodutide is a weekly glucagon and GLP-1 receptor dual agonist. Phase 2 obesity data showed substantial weight reduction at 2.4–4.8 mg weekly after forced titration.

Recommended Supplier — Survodutide Australia

Our products offer premium-grade research materials with independent testing at a leading Australian university. Every batch is strictly verified by RP-HPLC and LC-MS. For research purposes only.

Related Research — Australia

Explore similar research-grade peptides, selected to complement your research needs.

Tesamorelin + Ipamorelin

Tesamorelin target is 1-2 mg daily. Ipamorelin target....

Super Human Blend

One serving: L-Arginine 110 mg, L-Ornithine 110 mg,....

Semax + Selank

Short course. Intranasal preferred. Then 2-4 weeks off.....

Retatrutide + Cagrilintide

5+5 mg is a late stock, not a....
Select your currency
AUD Australian dollar